Capital Fund Management (CFM)
GBT

Capital Fund Management (CFM)’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Capital Fund Management (CFM)’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,500
Closed -$230K – 1698
2020
Q1 		$230K Buy
+4,500
New +$301K ﹤0.01% 1348

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Fund Management (CFM)'s GBT Position: Q3 2022 in Review

Capital Fund Management (CFM) sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 103,138 shares — an estimated $3.3M sold.

Capital Fund Management (CFM) first reported a position in GBT in Q3 2018 and held it in 7 quarters. The position peaked at $3.3M in Q1 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Capital Fund Management (CFM) reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 103,138 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $3.3M.
  • Capital Fund Management (CFM) first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 7 quarters.
  • Capital Fund Management (CFM)'s Global Blood Therapeutics, Inc. position peaked at $3.3M in Q1 2022.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2022, filed 14 Nov 2022.